Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22871223 | 1.00 | S1PR1 (0.46) | S1PR1S1PR3S1PR5S1PR4GBA1 | |
| SCHEMBL23251452 | 0.95 | S1PR1 (0.43) | S1PR1S1PR3S1PR5S1PR4GBA1 | |
| SCHEMBL28817875 | 0.93 | S1PR1 (0.40) | S1PR1S1PR3S1PR5S1PR4GBA1 | |
| SCHEMBL15473845 | 0.85 | GBA1 (0.37) | GBA1 | |
| SCHEMBL24926672 | 0.84 | S1PR1 (0.47) | S1PR1S1PR3S1PR5S1PR4GBA1 | |
| SCHEMBL24926618 | 0.82 | S1PR1 (0.44) | S1PR1S1PR3S1PR5S1PR4GBA1 | |
| SCHEMBL18963699 | 0.80 | GBA1 (0.36) | S1PR1S1PR3S1PR5GBA1 | |
| SCHEMBL13297119 | 0.80 | S1PR1 (0.43) | S1PR1S1PR3S1PR5S1PR4GBA1 | |
| SCHEMBL13297120 | 0.80 | S1PR1 (0.43) | S1PR1S1PR3S1PR5S1PR4GBA1 | |
| SCHEMBL13297118 | 0.80 | S1PR1 (0.43) | S1PR1S1PR3S1PR5S1PR4GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | S1PR1 1233/4885S1PR3 891/4885S1PR5 1091/4885 |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | S1PR1 1233/4885S1PR3 891/4885S1PR5 1091/4885 |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | S1PR1 1233/4885S1PR3 891/4885S1PR5 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.